REFERRAL AND CLINICAL GUIDELINES FOR LUNG CANCER

Issued: August 2009
Reviewed: September 2011/ May 2014/June 2014 (Chemotherapy/Radiotherapy)
Review date: 2016 (or earlier if new guidance available)
Index

Referral process 3
General Practitioner information arrangement 4
Suspicious x-ray policy 5
First clinic visit 6
Fitness for investigation/treatment 7
Referral guidelines for imaging in lung cancer 8
Histological pathways for lung cancer 8
Post investigation follow-up 9
General practitioner communication 9
Multi-disciplinary Team 9
PET/CT Scanning – Referral Strategy 10
Guidelines on indications for surgery for lung cancer 11
Guidelines for referral for radiotherapy and chemotherapy in lung cancer and mesothelioma 13
Interventional bronchoscopy/thoracoscopy 18
Management and investigation of Unilateral Pleural Effusions 21
Appx 1 – Non Small Cell Lung Cancer staging 23
Appx 2 – Stage Grouping TNM Subsets 25
Appx 3 – Performance status 26
Appx 4 – Small Cell Lung Cancer Staging 27
Appx 5 – Calculation of predicted post-operative FEV1 (ppoFEV1) 28
Appx 6 – Lung Cancer Histopathology Report 29
Appx 7 – Pathway for Specialist Mesothelioma MDT 31
REFERRAL PROCESS

- Appointment Pathway
- Suspicious X-Ray Policy
- Clinical Assessment
- Fitness for Investigation/Treatment
- Bronchoscopy/PCNB/Mediastinoscopy/Interventional bronchoscopy Procedures
- Radiology Protocols
- Follow-Up Arrangements
- Histology/Cytology Protocols
- MDTM Arrangements
- Surgery
- Radiotherapy
- Chemotherapy
General Practitioner Information Arrangement

REFERRAL PROCESS

1. Central information point providing telephone, fax, e-mail facilities

2. General Practice - Generic or Fast Track Lung Cancer Forms to be used

3. Hospital: In-house referrals from the Wards, Out-Patients or Casualty to be notified through the Central Referral System

APPOINTMENT PATHWAY - THE CASES OF SUSPECTED LUNG CANCER

1. Open Lung Cancer Referral Proforma

   ↓

   Fax/Mail to central referral point → Confirmation of receipt

   ↓

   Patient confirmation of appointment by letter or by telephone if clinic appointment within 48 Hours → GP informed by letter

   ↓

   Designated Lung Cancer Clinic with attending Lung Cancer Nurse

   ↓

   DNA’s - Further appointment arranged for within Seven Days → GP informed within 24 hours
SUSPICIOUS X-RAY POLICY

The following procedure is to be undertaken when a report of a routine chest x-ray raises the possibility of lung cancer.

Radiology Department

1. Inform the patient’s General Practitioner by fax or phone by the next working day of the unsuspected finding
2. Post the full confirmatory written report to the General Practitioner
3. Copy the report to the Chest Physician and the Chest Clinic and cancer data team if appropriate
4. In some cases it will be appropriate to arrange urgent CT scan

General Practitioner

The General Practitioner will initiate the referral under the 14 Day Rule.

Chest Clinic

The Chest Clinic or cancer data team will number and check referrals received against the copy x-ray reports.
FIRST CLINIC VISIT

1. **Clinical Assessment**
   
a) History including smoking habits, employment history (for suspected mesothelioma)

b) Examination - Height/Weight

c) Performance Status

2. **Investigations**
   
a) Spirometry

b) Chest X-Ray

c) Bloods - FBC/Serum Biochemistry/LFT's/Bone Profile/LDH

d) CT thorax/upper abdo to be arranged urgently or on same day (if not already done)

e) Bronchoscopy to be arranged if appropriate

3. **Patient Information**

Provision of literature and contact arrangements by Lung Cancer Nurse
FITNESS FOR INVESTIGATION/TREATMENT

All patients should be considered for investigations to obtain histological or cytological confirmation of their disease.

Patients who after the initial assessment are deemed too seriously ill for further investigation should be discussed at the MDTM for registration and consideration for supportive care without a confirmatory histological diagnosis.

Patients who decline investigations or treatment should similarly be reviewed and a management strategy documented.

BRONCHOSCOPY

1. **Consent**
   
   Informed consent to be obtained by the Operator

2. **Patient Information**
   
   Arrangements for the procedure to be explained by the Chest Clinic staff and with accompanying literature which should include a contact telephone number for any subsequent enquiries.

3. **Follow-up**
   
   Follow-up arrangements to be initiated at the first visit for next results clinic after bronchoscopy or following CT/Histology/MDTM review.

CT Guided Lung Biopsy

1. **Suitability.** Most lung and mediastinal lesions can be considered for CT Guided Lung biopsy However peripheral lesions >10mm are most suitable.

2. **Fitness.** Resting hypoxia and impaired lung function (FEV1 < 1 litre, or <40%) are relative contraindications. Cognitive impairment which renders the patient uncooperative is a near absolute contraindication.

3. **Consent.** Outline consent should be obtained in the OPC, and written consent obtained by the operator on or before the day of procedure. Patient information literature should be given at the first opportunity.
REFERRAL GUIDELINES FOR IMAGING IN LUNG CANCER

CT Scan Referral

1. Requests received on a standard CT request card or by electronic referral.

2. Consultant Radiologist vets request to determine the appropriate protocol and level of urgency.

3. Scans are booked on the next available urgent slot. Where possible and appropriate, scans will be performed on or before the day of clinic attendance. All scans are reported by a Consultant Radiologist or designated Registrar.

4. Where confirmed histology is available, a report should contain the following features:
   - Tumour site and maximum dimension
   - Multiplicity or satellite lesions
   - Evidence of pleural or fissural involvement
   - Evidence of pericardial involvement
   - Presence of associated pneumonitis or collapse
   - Presence of ipsilateral or contralateral lung nodules (T3 / T4 / M1a)
   - Evidence of mediastinal invasion, and comment on whether only mediastinal fat invaded
   - Proximity to the main carina or carina of the main bronchi
   - Location and short axis diameter of nodes
   - Evidence of distant metastasis

5. From this, a TNM stage will be offered, or alternative TNM stages dependent upon further investigation and a radiological tumour stage.

6. If there is a doubt as to histology no definite TNM stage is offered. A provisional TNM stage contingent upon histology may be offered if possible. In this instance, protocol indicating tumour stage should be confirmed at the MDT once histology is confirmed.

7. If reports identify a previously unsuspected lung cancer, a report should be faxed to the GP within 24 hours of the report being typed and a copy of the report sent to the MDT secretary.

HISTOLOGICAL PATHWAYS FOR LUNG CANCER

The sample (cytology, biopsy or resected tumour) is reported as promptly as possible i.e. within 48 hours for biopsies and cytology and 5 working days for resected specimens.

A report is then sent to the requesting clinician so that details of the specimen are available at the weekly MDT. In addition, a copy report of the resected specimen should be sent to the respective lung cancer nurse to facilitate further discussion at the MDT.

The vast majority of malignant tumours will be either small cell, squamous or adenocarcinoma and it is recognised that H and E staining alone will be sufficient to categorise most tumours appropriately. In difficult cases immunohistochemical and mucin staining may be required.
including a neuroendocrine panel (chromogranin, synaptophysin and CD56) as well as CK7, TTF1 and CK5/6. The reporting of resected tumours will be based on the Pathology Lung Cancer National Minimal Data Set (enclosed in appendix 6). Selected adenocarcinoma cases, discussed at MDT, should be sent for EGfR and/or ALK assay. These patients will usually be those with adenocarcinoma and little smoking history.

POST INVESTIGATION FOLLOW-UP

1. **Bronchoscopy**

   Follow-up appointment to be made at the first visit for the next results clinic, or appointment to be made subsequently when the MDTM/Histology/CT results are available.

2. **CT Scan**

   Copies to Clinicians and Lung Cancer Nurses for urgent attention.

3. **PCNB/Pleural biopsy/Mediastinoscopy/VAT Biopsy**

   Appointment to be given to the patient after the procedure for the next clinic or the Lung Cancer Nurse to be contacted to arrange further supervision.

4. **Histology/Cytology Report**

   Copies to Clinicians and Lung Cancer Nurses.

GENERAL PRACTITIONER COMMUNICATION

The General Practitioner must be informed by the end of the following working day of all patients who have been informed of their diagnosis of lung cancer.

1. **Out-Patients**

   The General Practitioner/Surgery would be notified by telephone on the next working day that the patient had been informed of the diagnosis. The Clinician should ensure that a full report is available to the General Practitioner by the end of the following working day.

2. **In-Patients**

   The medical team/Consultant office is responsible for telephone/fax confirmation of the patient information.

   The record of date/time/author of the fax/telephone information should be recorded in the patient’s notes.
MDT

Once investigations have been completed all patients should be discussed at the weekly MDT meeting where individual treatment options will be determined. The completed MDT proforma would be an accepted referral letter for surgery/oncology/palliative care. All patients deemed suitable for radical treatment (surgery, radiotherapy or chemoradiation) should be referred for a PET scan via the electronic referral form.

PET/CT SCANNING - REFERRAL STRATEGY

Clinical Indications in respiratory cancers

Following detailed discussion and taking into account current evidence base the following clinical indications were agreed.

1. Evaluation of solitary pulmonary nodules
2. Staging of non-small cell lung cancer

Patients meeting the above criteria are discussed in the local MDT. Referral should be made on the electronic request form, which must be fully completed, or it will be returned. This is in order to comply with IRMER regulations and the requesting process. Particular care should be taken in giving a full relevant clinical history and noting whether a patient is diabetic.

GUIDELINES ON INDICATIONS FOR SURGERY FOR LUNG CANCER

Surgery for stage I-IIIA should be considered if patient has the necessary respiratory reserve and is deemed medically fit for major surgery. A suitably completed MDT record is appropriate for referral

Based on the BTS Guidelines from 2000

FITNESS

a) Age:
   i) Perioperative morbidity increases with advancing age. Elderly patients undergoing lung resection are more likely to require intensive perioperative support. Preoperatively, a careful assessment of co-morbidity needs to be made.
   ii) Surgery for clinically stage I and II disease can be as effective in patients over 70 years as in younger patients. Such patients should be considered for surgical treatment regardless of age.
   iii) Age over 80 alone is not a contraindication to lobectomy or wedge resection for clinically stage I disease.
   iv) Pneumonectomy is associated with a higher mortality risk in the elderly. Age should be a factor in deciding suitability for pneumonectomy.

Further Assessment and Planning of Patients for Surgery (Based on NICE Guidance 2011)
Perform spirometry in all patients being considered for treatment with curative intent. Measure TLCO if breathlessness is disproportionate or there is other lung pathology (for example, lung fibrosis).

Offer patients surgery if they have an FEV1 within normal limits and good exercise tolerance.

When considering surgery perform a segment count to predict postoperative lung function.

Offer patients with predicted postoperative FEV1 or TLCO below the recommended limit of 30% the option of undergoing surgery if they accept the risks of dyspnoea and associated complications.

Consider using shuttle walk testing (using a distance walked of more than 400 m as a cut-off for good function) to assess fitness of patients with moderate to high risk of postoperative dyspnoea.

Consider cardiopulmonary exercise testing to measure VO2 max and assess lung function in patients with moderate to high risk of postoperative dyspnoea, using more than 15 ml/kg/minute as a cut-off for good function.

Offer patients with NSCLC who are medically fit and suitable for treatment with curative intent, lobectomy (either open or thoracoscopic) as the treatment of first choice. For patients with borderline fitness and smaller tumours (T1a–b, N0, M0), consider lung parenchymal-sparing operations (segmentectomy or wedge resection) if a complete resection can be achieved.

Offer more extensive surgery (bronchoangioplastic surgery, bilobectomy, pneumonectomy) only when needed to obtain clear margins.

Perform hilar and mediastinal lymph node sampling or en bloc resection for all patients undergoing surgery with curative intent.

b) Cardiovascular Fitness:

- Previous MI – interval of 6 weeks + cardiological opinion
- Previous CABG – no increased risk if asymptomatic
- Previous CVA – Doppler for carotid artery stenosis
- Murmur – ECHO
- Angina or SOB due to cardiac disease – exercise test

c) Performance status:

WHO 0,1 or 2

e) Special Situations:

Advanced local disease: consider for surgery only if N0/N1

i) Chest wall invasion: Potentially operable if T3N0. Pain is a good predictor. CT 90% accurate. MRI may be indicated. High resolution Ultrasound is also a very useful modality.

ii) Adherence to vertebral column: surgery may be contemplated in individual cases. Erosion = inoperable.
iii) Superior sulcus tumours: Horner’s syndrome, invasion of brachial plexus and subclavian vessels or vertebrae = inoperable. In this situation induction treatment with chemotherapy and radiotherapy might be attempted to downsize the tumour with subsequent surgery as an option for very selected patients.

iv) Small cell lung cancer: for stage I only (T1N0, T2N0)

Following resection patients should be discussed at the MDT for consideration of adjuvant treatment (see under radiotherapy/chemotherapy section).

LSCCN Lung Network second opinion guidance

Cardiothoracic Surgery

1) Internal

It is felt that referral Cardiothoracic surgeons outside the network will rarely be necessary, as a full range of techniques and procedures are now available from the surgeons based at Blackpool Victoria Hospital. However it is recognised that in difficult or complex cases, the opinion of more than one surgeon may be valuable. To this end, the network has instituted a mechanism for obtaining internal second opinions, which has been agreed with the Cardiothoracic surgeons at Blackpool Victoria. Should a referring MDT feel that a particular patient requires discussion with a second surgeon, a referral should be made in writing to one of the Cardiothoracic surgeons with a sub speciality interest in thoracic surgery, who have kindly agreed to provide this service. These are:

Mr J Zacharias
Mr N Bittar
Mr A Duncan
Cardiothoracic Surgery
Blackpool Victoria Hospital
Whinney Heys Road
Blackpool
FY3 8NR Fax to 01253 657844

2) External

Referrals for Cardiothoracic surgical opinions outside the network, should, it is envisaged, be only occasional, however should a referring MDT deem this necessary, then a referral should be made to the clinician of your choice. For reference purposes this should be copied to the chair of the Lung NSSG together with a note of the outcome, if any. It is emphasised that the referring MDT retains clinical responsibility for the patient at all times.
GUIDELINES FOR REFERRAL FOR RADIOTHERAPY AND CHEMOTHERAPY IN LUNG CANCER AND MESOTHELIOMA

NON SMALL CELL LUNG CANCER

Appropriate treatment choice for individual patients depends largely on the stage of disease at presentation and their performance status.

Investigations to determine these should be performed prior to referral to an oncologist.

All patients should be discussed at an MDT meeting

Radical Radiotherapy

Stages I, II and selected III patients may be suitable if either surgery is declined or the patient is medically unfit for surgery. These patients would be offered radical radiotherapy with 55Gy/20# over 4 weeks.

Combined modality treatment concurrently with chemotherapy (Navelbine/Cisplatin week 1+4) is available for patients with good PS and confirmed histological diagnosis for Stage III. It should be made clear to the patient that conventional radiotherapy is inferior in outcome to surgical resection but could be appropriate if the patient is not medically fit for resection.

Postoperative radiotherapy

Patients with incompletely resected disease should be considered for post-operative radiotherapy (50Gy in 20# over 4 weeks) +/- adjuvant chemotherapy with Vinorelbine/Cisplatin if their PS is good.

Post operative radiotherapy for unexpected N2 disease is the subject of a clinical trial (Lung ART)

Stereoablative Body Radiotherapy (SABR):

This involves high intensity radiotherapy to a small focal area of the lung. Patients with relatively small tumours who would otherwise be suitable for surgical therapy but who are unsuitable by reason of co-morbidity or personal preference should be considered for referral for this service. Referrals should be directed to – Clatterbridge, Christie or Leeds Hospitals. This service is being developed at LTHTR

Inclusion Criteria:

Patients may be suitable if they fulfil the following criteria:
- T1-T3 N0 M0
- Tumour<5 cm
- PS 0-2 (PS 3 may be suitable if due to comorbidity)
- Peripheral tumour (> 20 mm distal to origin of segmental bronchus)
Histological or Radiological Features of Lung Cancer
Lung function not a contra – indication
MDT Discussion

Chemotherapy

Neoadjuvant chemotherapy
Neoadjuvant chemotherapy is currently not advised outside the context of a clinical trial in Stage I and II patients.
Selected Stage III patients may be suitable for vinorelbine 25mg/m2 day 1+8 (or oral Vinorelbine at 60mg/m2 day 1 and 8) and cisplatin 80mg/m2 day 1 q 3/52 x 4 cycles prior to considering surgical resection or radical radiotherapy. Carboplatin (AUC5) can be considered in place of cisplatin in patients with poor renal function.

Adjuvant Chemotherapy
Adjuvant chemotherapy with Vinorelbine 25mg/m2 day 1+8 (or oral Vinorelbine 60mg/m2 day 1 and 8) and Cisplatin 80mg/m2 day 1 q 3/52 x 4 cycles should be offered to patients who had a complete resection for Stage II and III disease. Carboplatin (AUC5) can be considered in place of cisplatin in patients with poor renal function. Patients with Stage IB disease should be discussed on an individual basis as currently there is no good evidence to support routine adjuvant chemotherapy.

Advanced Disease

1st line therapy:
Patients with small volume Stage III disease who are medically unfit for surgical resection should be considered for combined modality treatment with chemotherapy and radiotherapy. This could either be given sequentially or concurrently. The chemotherapy regimen consists of Cisplatin +/- Vinorelbine, radiotherapy would be given over 4 weeks.
Patients with Stage III/IV disease unsuitable for radical treatment who have PS 0-1 should be considered for palliative chemotherapy. Depending on the histological subtype chemotherapy for non-squamous histology should be a platinum/Pemetrexed combination, squamous cell carcinoma with Gemcitabine or Vinorelbine and Carboplatin. Some patients with Stage III/IV disease and PS 2 could be considered for Carboplatin and weekly Paclitaxel.
All non-squamous histological subtypes should be sent for EGFR mutation testing. If an activating mutation is confirmed, these patients should be treated with an EGFR Tyrosine Kinase Inhibitor (Gefitinib, Erlotinib, or Afatinib) in the first line setting, rather than standard chemotherapy.
All patients with adenocarcinoma histology should be sent for ALK fusion gene testing.

1st line maintenance chemotherapy
Patients with non-squamous histology who had at least stable disease after 4 cycles of Cisplatin/Pemetrexed should be offered maintenance treatment with Pemetrexed every 3 weeks until disease progression. Funding needs to be secured from the Cancer Drugs Fund before cycle 1 of maintenance therapy (NICE assessment is awaited).
Patients not wishing to have maintenance with Pemetrexed could be considered for the PIN trial, comparing maintenance treatment with a PARP inhibitor to placebo.
Patients who achieved stable disease as best response to initial chemotherapy (regardless of histological subtype) could be considered for the PIN trial or maintenance Erlotinib.

2nd line therapy:
Patients with advanced disease who do not respond to, progress or relapse after 1st line chemotherapy and whose PS is 0-1 should be considered for 2nd line chemotherapy. Options include Docetaxel 75mg/m2 every 3/52 for 4 cycles +/- Nintedanib (within EAP); or Erlotinib 150mg daily p.o or with Crizotinib (or entry into a trial) for patients who are ALK fusion gene positive.

Patients with known EGFR mutation who progress after an initial response to TKI should be considered for systemic chemotherapy or referred to the Christie Hospital Phase I/II Unit for trials.

Patients should be reviewed at the beginning of a new cycle of treatment by the clinician and at disease progression treatment should be withdrawn.

Further lines of chemotherapy depend on previous response and duration of response to treatment, fitness and are at the discretion of the treating clinician.

Palliative Radiotherapy

Palliative radiotherapy to the thorax should be considered for patients with locally advanced NSCLC for whom radical radiotherapy is unsuitable.

Patients with good performance status (WHO 0-1) may benefit from “high dose” fractionated treatment. In this group there is a 36% 1yr and 12% 2yr survival.

Those with WHO performance status 2-3 who are symptomatic from their disease are likely to be suitable for a shorter treatment. The median duration of palliation has been shown to be at least 50% of their remaining life.

For those patients with poor performance status who are asymptomatic, it may be decided to hold XRT in reserve until symptomatic disease progression.

Symptoms that are most likely to be helped by radiotherapy are:

- Haemoptysis
- Chest pain
- Dysphagia due to extrinsic oesophageal compression
- Cough

Metastasis – Radiotherapy may help in metastatic lung cancer especially in patients with:

- Bone metastases
- Skin metastases
- Brain metastases (especially in the under 65 year olds who have a good performance score and no symptoms from their metastatic disease)
Patients with no more than 3 brain metastases on MRI scan who are fit with an anticipated reasonable life-expectancy should be discussed at the neuro-oncology MDT as they might fulfil the criteria for debulking surgery and/or stereotactic radiotherapy.

**SMALL CELL LUNG CANCER**

Appropriate treatment choice for individual patients depends largely on the stage of disease at presentation and their performance status. Stage 1 may be considered for surgical resection (followed by adjuvant chemo- and radiotherapy).

Investigations to determine these should be performed prior to referral to an oncologist. This includes recent blood tests (FBC, U/E, LDH, LFT)

**Limited Stage Disease, good Manchester Score (0/1)**

Fit patients should be offered concurrent chemoradiation with Cisplatin 80mg/m2 day1 and Etoposide 100mg/m2 day 1-3 x 4-6 cycles (oral Etoposide 200mg/m2 can be substituted for days 2-3). Radiotherapy will start with cycle 2 or 3.

A dose of 40Gy in 15 fractions will be given to the thorax.

Patients with initial disease volume too large to be treated with radical radiation should be reassessed after induction chemotherapy with platinum based chemotherapy.

Following a good response patients should be considered for prophylactic cranial irradiation (25Gy/10#).

**Limited stage, poor Manchester Score OR Extensive stage, good Manchester Score**

Combination chemotherapy with Carboplatin AUC5 day1 and Etoposide 100mg/m2 day 1-3 (oral Etoposide 200mg/m2 can be substituted for days 2-3) followed by thoracic consolidation radiotherapy (for limited stage patients only) should be considered for these patients.

All patients should receive primary prophylaxis with GCSF.

**Extensive Stage Disease, poor Manchester score**

Treatment with single agent Carboplatin AUC5 could be considered as alternative to combination treatment initially. However, as soon as the performance status improves patients should be reassessed for use of combination chemotherapy.

Patients under the age of 75 who had at least stable disease following their first line chemotherapy should be considered for prophylactic cranial irradiation (20Gy / 5#).

Radiotherapy may also be used for symptom control.

**Second Line Chemotherapy**

Patients who recur more than 3 months after completion of 1st line treatment should be considered chemosensitive and may be offered further chemotherapy with a platinum
rechallenge, topotecan and CAV. Their overall prognosis is however very poor and median survival is < 4 months. Attempts should be made to recruit these patients into a national trial if their performance status is good.

**Metastasis** – Radiotherapy may help in metastatic small cell lung cancer especially in patients with:
- Bone metastasis
- Brain metastasis
- Skin metastasis

**MESOTHELIOMA**

Appropriate treatment choice for individual patients depends largely on the stage of disease at presentation and their performance status.

Investigations to determine these should be performed prior to referral to an oncologist and special consideration should be given to entry into one of the interventional trials at LTHTR (PI Dr Munavvar).

All patients should be discussed at an MDT meeting and patients with diagnostic dilemmas or where more invasive treatment is planned should be discussed at the Network Mesothelioma MDT (see Appendix 7).

**Surgery**

Decortication and pleurectomy can be considered in selected patients. Entry into surgical trials (if available) should be considered. VATS pleurodesis may be useful in the treatment of recurrent pleural effusion.

**Radiotherapy**

The role of prophylactic irradiation of chest drain sites is controversial. Patients with visible scars following chest wall intervention who have not got an indwelling pleural catheter should be considered for the PIT trial comparing prophylactic chest wall irradiation to observation only. Palliative radiotherapy to areas of tumour causing symptoms from local invasion may be beneficial.

**Metastasis** – Radiotherapy may help in metastatic mesothelioma especially in patients with:
- Bone metastasis
- Brain metastasis
- Skin metastasis
Chemotherapy

Patients with PS 0-1 may be considered for palliative chemotherapy with a Pemetrexed and Platinun combination. Patients should be monitored with regards to response and side effects whilst on this treatment. Up to 6 cycles can be given.

Patients can be considered for second-line treatment or clinical trials.
INTERVENTIONAL BRONCHOSCOPY/THORACOSCOPY AT PRESTON

Among the many areas of respiratory medicine which have been revolutionised by technological advances, bronchoscopy is one of the most obvious examples. Parallel to the development of ever finer flexible bronchoscopes and working tools, there has been considerable expansion in the diagnostic and therapeutic techniques that can be practised via the bronchoscope, particularly in lung cancer.

Therapeutic Flexible Bronchoscopy

Tracheo-bronchial obstruction due to malignant processes can lead to recurrent pneumonia, respiratory insufficiency and death. Curative resection is not possible in the majority of cases, and treatment instead is focussed upon palliation. Techniques available for treatment of tracheobronchial obstruction include electrocautery, argon plasma coagulation, airway stents, laser therapy, cryotherapy, brachytherapy, balloon dilatation and photodynamic therapy. At Preston, we are able to offer majority of these techniques.

Endobronchial Electrocautery (Diathermy) and Argon Plasma Coagulation

Indications: These techniques are particularly useful when there is a clear evidence of endobronchial disease and the patient presents with one of the following:

1. Marked volume loss such as lobar or extensive lung collapse.
2. Stridor.
3. Worsening dyspnoea.
4. Post-obstructive pneumonia.
5. Haemoptysis caused by an accessible, visible lesion.

The following points are worth noting with regard to diathermy and argon plasma coagulation.

1. The more central the obstruction in the bronchus, the greater the likelihood of palliation. For more distal obstruction, benefit achieved is small. However, treatment of tracheal lesions carries a slightly greater risk.
2. These techniques are best considered after the more established treatment options have been looked at, such as surgery, radiotherapy and chemotherapy.
3. Diathermy is not indicated in the presence of massive haemoptysis, as adequate visualisation is essential to this technique, and in that situation surgical help with rigid bronchoscopy or interventional vascular radiology input would be needed.

Tracheobronchial Stenting

The ultraflex (Nitinol) stent can be placed to relieve acute or sub-acute obstruction of the central airways, in patients who present with stridor, marked volume loss, increasing dyspnoea and post-obstructive pneumonia. This technique is useful essentially where the lesion is ‘extrinsic’ causing obstruction. Also, they are most effective where there is a relatively short segment of stenosis in the mid/lower trachea, right main and intermediate bronchi, and the left main
bronchus (in rare situations where there is a combination of localised intrinsic and extrinsic obstruction, diathermy debulking can be followed up with stenting).

Stenting can also be effective in the presence of a localised tracheo-oesophageal fistula, where double stenting is required, that is tracheal followed by oesophageal stent.

Stent placement through the flexible bronchoscope is not possible when:

(a) There is a high tracheal lesion.
(b) The obstruction extends from the lower trachea into both main bronchi – where rigid bronchoscopy and an inverted Y stent is indicated.
(c) When the mucosa is involved by an extremely vascular, fragile process.

Transbronchial Needle Aspiration (TBNA)

Over the last decade, TBNA has improved the diagnostic yield and extended the role of flexible bronchoscopy in the evaluation of mediastinal pathology and the diagnosis and staging of lung cancer.

Indications:

1. Peri-bronchial disease causing extrinsic compression.
2. Sub-mucosal disease.
3. Necrotic, haemorrhagic endobronchial lesions.
4. Mediastinal and/or hilar lymphadenopathy – to help diagnose malignant and benign lesions.

TBNA is particularly safe and carries a high yield when the abnormality is in the sub-carinal, right para-tracheal or right hilar region.

EBUS-Guided TBNA

Endobronchial ultrasound-guided transbronchial needle aspiration is a new technique which has largely superseded TBNA in majority of situations. This is a procedure using a dedicated bronchoscope with a convex ultrasound probe at the tip. Real time ultrasound images of mediastinal nodes are obtained, along with Doppler flow to differentiate blood vessels from the lymph nodes. Through a side port, a needle can be advanced into the lymph node and targeted samples can be obtained. With practice, this technique has a greater than 90% positive yield and samples can be aspirated from a variety of lymph nodes including sub-carinal, right para-tracheal, left para-tracheal, right hilar and left hilar regions. With the advantage of dynamic ultrasound guidance, larger samples are acquired and the procedure carries a very low risk of bleeding.

Therefore, any patient with unexplained or malignant appearing mediastinal/ hilar adenopathy can be referred for this procedure. In addition, peribronchial lesions can be diagnosed and mediastinal staging can be completed.
Semi-Rigid Medical Thoracoscopy

The technique involves a single incision of just over a centimetre in the mid-axillary line under local anaesthesia and standard sedation. It is performed in the Endoscopy Suite and the patient is usually required to stay overnight after the procedure.

Indications

1. Undiagnosed unilateral, exudative pleural effusion – drainage, pleural biopsy and if appropriate TALC pleurodesis can be performed in one sitting
2. Hydropneumothorax or pneumothorax when an underlying parietal pleural pathology is suspected.
3. Recurrent pleural effusions – for complete drainage and TALC pleurodesis.
4. Early cases of empyema.

All such patients should have normal clotting, liver and renal function, and a contrast enhanced CT scan of the thorax, besides a recent chest x-ray prior to the procedure.

Guidelines for Referral

1. If the indication for the procedure is obvious, as outlined above, please fax a referral addressed to Dr Munavvar on 01772 522412, and arrange for the images to be uploaded to LTHT PACS.
2. It is essential that the patient’s clotting profile, renal and hepatic function are satisfactory. If the patient is on warfarin, this will need to be discontinued for about seven days before the procedure. The same applies to Clopidogrel.
3. In cases of therapeutic bronchoscopy, the patient and relatives need to be aware that the treatment is purely for palliation of symptoms/obstruction. Also, the risk of bleeding and other usual complications of bronchoscopy need to be mentioned. Further details of the possible complications of the specific procedure will be outlined when the patient is seen.
4. The patient will often need to stay overnight after the procedure on the respiratory ward.
5. Patients referred for stenting will occasionally have to stay for a few days in the hospital, as the stents may have to be measured and ordered after the initial assessment, and the patient may require a further bronchoscopy after the stent is deployed.

Contact details are as follows:
Fax No:01772 522810
Tel Nos: 01772 522416 / 522412 / 522189
Management and Investigation of Unilateral Pleural Effusions

1. **Take a full history and perform a clinical examination**
   Clinical assessment can be used to identify transudative effusions which will not require sampling and can therefore be managed medically.

2. **Perform pleural aspiration**
   Collect a 50 ml sample of the pleural fluid using a 21G (green) needle. Note the colour and odour of the fluid; if it is turbid, collect an additional sample using an ABG syringe and analyse it immediately using the ABG machine.

3. **Request appropriate analysis of the pleural fluid**
   Add 10 ml to two universal containers (for cytology and AAFB/gram stain/TB culture), 10 ml to each of anaerobic and aerobic blood culture bottles and the remainder to citrate (yellow, for glucose), gel (brown, for LDH/protein) tubes. If the fluid is frankly blood-stained, add 2 ml to an EDTA (red) tube to measure the haematocrit. Ensure the sample is analysed within 4 hours.

4. **Apply Light’s Criteria to the results received from the laboratory**
   The fluid is an exudate if \( \frac{[\text{protein}]_p}{[\text{protein}]_s} > 0.5 \) or \( \frac{[\text{LDH}]_p}{[\text{LDH}]_s} > 0.6 \)

5. **Interpret the results**
   - \( \text{pH} < 7.2 \) with evidence of infection or positive gram stain
     Empyema requiring prompt tube drainage; refer to the Respiratory team
   - **Transudate**
     Drain only if there is respiratory distress; treat the underlying cause.
   - **Exudate**
     Request a contrast-enhanced CT of the thorax optimised for pleural assessment and refer to the Respiratory Team.

**RESPIRATORY PHYSICIANS**

6. **Discuss**
   The contrast-enhanced CT scan of the thorax should be reviewed ASAP with a radiologist or discussed in the next Chest Radiology meeting.
Direct as necessary for tissue diagnosis or case review

Thoracoscopy
Direct visualisation of any pleural lesions. Sampling, drainage and talc poudrage performed in one sitting. Semi-rigid thoracoscopy (minimally invasive, under LA and sedation)

Image guided Pleural biopsy- Ultrasound or CT guided- discuss with Consultant Radiologist

VATS
Requires GA and single lung ventilation- discuss with Cardio-thoracic Surgeon

Algorithm for investigation of Pleural Effusion

Clinical Features of Exudate

- Empyema
- Chylothorax or Haemothorax
- Yes
  - Pleural aspiration
  - Cyto, biochem, micro pH
- Transudate
  - Treat cause
- No diagnosis
  - Refer to a Chest Physician
  - Contrast enhanced CT
  - Pleural tissue by Image Guided Bx or Thorascopy Further samples including AFB
**Appendix 1**

**Non Small Cell Lung Cancer staging**

Revised Staging System. See [http://chestjournal.chestpubs.org/content/136/1/260.full.pdf](http://chestjournal.chestpubs.org/content/136/1/260.full.pdf)

**T-primary tumour**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>TX</td>
<td>Primary Tumour cannot be assessed</td>
</tr>
<tr>
<td>T0</td>
<td>No evidence of Primary Tumour</td>
</tr>
<tr>
<td>Tis</td>
<td>Carcinoma in situ</td>
</tr>
<tr>
<td>T1</td>
<td>Tumour 3cm or less in greatest dimension, surrounded by lung or visceral pleura, not involving the main bronchus.</td>
</tr>
<tr>
<td>T1a</td>
<td>Tumour =&lt; 2cm in greatest dimension</td>
</tr>
<tr>
<td>T1b</td>
<td>Tumour &gt;2cm but =&lt; 3cm in greatest dimension</td>
</tr>
<tr>
<td>T2</td>
<td>Tumour &gt;3 cm but =&lt;7cm or with any of the following features of size or extent (Tumours with these features are classified as T2a if &lt;5cm):</td>
</tr>
<tr>
<td></td>
<td>- More than 3cm in maximum dimension</td>
</tr>
<tr>
<td></td>
<td>- Involves main bronchus, 2cm or more distal to the carina</td>
</tr>
<tr>
<td></td>
<td>- Invades visceral pleura</td>
</tr>
<tr>
<td></td>
<td>- Associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not involve the entire lung</td>
</tr>
<tr>
<td>T2a</td>
<td>Tumour &gt;3cm but =&lt;5cm in greatest dimension</td>
</tr>
<tr>
<td>T2b</td>
<td>Tumour &gt;5cm but =&lt;7cm in greatest dimension</td>
</tr>
<tr>
<td>T3</td>
<td>Tumour &gt;7cm or one that directly invades any of the following:</td>
</tr>
<tr>
<td></td>
<td>- Chest wall inc. superior sulcus</td>
</tr>
<tr>
<td></td>
<td>- Diaphragm</td>
</tr>
<tr>
<td></td>
<td>- Phrenic Nerve</td>
</tr>
<tr>
<td></td>
<td>- Mediastinal pleura</td>
</tr>
<tr>
<td></td>
<td>- Parietal pericardium</td>
</tr>
<tr>
<td></td>
<td>or tumour in the main bronchus less than 2cm distal to the carina but not involving the carina</td>
</tr>
<tr>
<td></td>
<td>or associated atelectasis or obstructive pneumonitis of the entire lung</td>
</tr>
<tr>
<td></td>
<td>or separate tumour nodule or nodules in the same lobe</td>
</tr>
<tr>
<td>T4</td>
<td>Tumour of any size that invades any of the following:</td>
</tr>
<tr>
<td></td>
<td>- Mediastinum</td>
</tr>
<tr>
<td></td>
<td>- Heart</td>
</tr>
</tbody>
</table>
- Great vessels
- Trachea
- Recurrent laryngeal nerve
- Oesophagus
- Vertebral body
- Carina
- Separate tumour nodules in a different ipsilateral lobe

**N-REGIONAL LYMPH NODES**

**NX** Regional lymph nodes cannot be assessed

**N1** Metastasis in ipsilateral peribronchial and/or subcarinal lymph nodes and intrapulmonary nodes

**N2** Metastasis in ipsilateral mediastinal and/or subcarinal lymph node(s)

**N3** Metastasis in contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalene or supraclavicular lymph nodes

**M-DISTANT METASTASIS**

**MX** Distant metastasis cannot be assessed

**M0** No distant metastasis

**M1** Distant metastasis (includes separate tumour nodule(s) in a different lobe)

**M1a** Separate tumour nodules in a contralateral lobe; tumour with pleural nodules or malignant pleural or pericardial effusion.

**M1b** Distant metastasis
### Stage Grouping TNM Subsets

#### Table 8. Proposed TNM Stage Groupings

<table>
<thead>
<tr>
<th>Occult Carcinoma</th>
<th>T</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA</td>
<td>T1a, b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T1a, b</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2b</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T1, T2</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1, N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T4</td>
<td>N0, N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T4</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>Any N</td>
<td>M1a, b</td>
</tr>
</tbody>
</table>
## Performance Status

<table>
<thead>
<tr>
<th>KP</th>
<th>WHO</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>100</td>
<td>0</td>
<td>Normal, no complaints, no evidence of disease</td>
</tr>
<tr>
<td>90</td>
<td>0</td>
<td>Able to carry on normal activity; minor signs or symptoms of disease</td>
</tr>
<tr>
<td>80</td>
<td>1</td>
<td>Normal activity with effort, some signs and symptoms of disease</td>
</tr>
<tr>
<td>70</td>
<td>1</td>
<td>Cares for self but unable to carry on normal activity or do work</td>
</tr>
<tr>
<td>60</td>
<td>2</td>
<td>Requires occasional assistance but is able to care for most personal needs</td>
</tr>
<tr>
<td>50</td>
<td>2</td>
<td>Requires considerable assistance and frequent medical care</td>
</tr>
<tr>
<td>40</td>
<td>3</td>
<td>Disabled; requires special care and assistance</td>
</tr>
<tr>
<td>30</td>
<td>3</td>
<td>Severely disabled; hospitalisation indicated, death no imminent</td>
</tr>
<tr>
<td>20</td>
<td>4</td>
<td>Very ill; hospitalisation and active supportive care necessary</td>
</tr>
<tr>
<td>10</td>
<td>4</td>
<td>Moribund</td>
</tr>
<tr>
<td>0</td>
<td>4</td>
<td>Dead</td>
</tr>
</tbody>
</table>
Small Cell Lung Cancer Staging

Small Cell Lung Cancer Staging should be done according to the TNM staging in addition to description of limited/extensive stage disease

**Limited stage** – disease confined to one hemithorax (can include ipsilateral SCF and contralateral hilar nodes but excludes pleural effusion)

**Extensive stage** – disease beyond one hemithorax

Prognostic factors

- LD vs ED
- KP >60 vs ≤ 60
- Serum Na (low vs normal)
- Serum LDH (normal vs high)
- Serum alk phos (normal vs high)
- Each adverse features scores +1

Scores of 0 and 1 have better prognosis
Appendix 5

Calculation of predicted post-operative FEV1 (ppoFEV1)

\[ \text{ppoFEV1} = \frac{\text{pre FEV1} \times (19 - \text{segments to be removed})}{19} \]

If any obstructed segments:

\[ \text{ppoFEV1} = \frac{\text{pre FEV1} \times (19 - a - b)}{19 - a} \]

\(a = \) no of obstructed segments
\(b = \) no of obstructed segments to be resected

Right upper lobe   = 3   Left upper lobe   = 3
Middle lobe        = 2   Lingula            = 2
Right lower lobe   = 5   Left lower lobe   = 4
### Appendix 6

#### Dataset for lung cancer histopathology reports (3rd edition)

**Histopathology reporting proforma for lung cancer resection specimens**

<table>
<thead>
<tr>
<th>Surname</th>
<th>Forenames</th>
<th>Date of birth</th>
<th>Sex</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital</td>
<td>Hospital no</td>
<td>NHS/CHI no</td>
<td></td>
</tr>
<tr>
<td>Date of receipt</td>
<td>Date of reporting</td>
<td>Report no</td>
<td></td>
</tr>
<tr>
<td>Pathologist</td>
<td>Surgeon/physician</td>
<td>Lab no</td>
<td></td>
</tr>
</tbody>
</table>

**Previous treatment (neoadjuvant chemotherapy/radiotherapy)**

- Yes ☐  No ☐

**Specimen type**

- **Right lung** ☐ VATS ☐
- **Left lung** ☐ VATS converted to open ☐ Open ☐
- **Single wedge resection** ☐ Pneumonectomy (extra-pericardial) ☐
- **Multiple wedge resections** ☐ Pneumonectomy (intra-pericardial) ☐
- **Segmentectomy** ☐
- **Lobectomy/bi-lobectomy** ☐ Other ☐ (specify) ............................

**Other surgical procedures**

- **Sleeve resection** ☐ Other (e.g. chest wall) ............................

**Macroscopic features**

- **Main bronchus within 20 mm of carina (T3) (if known)** ☐
- **Main bronchus more than 20 mm from carina (T2)** ☐
- **Location of tumour:** ..........................................................
  - Hilar/endobronchial/central ☐
  - Right upper lobe ☐ Right middle lobe ☐ Right lower lobe ☐
  - Left upper lobe ☐ Left lower lobe ☐ Not assessable ☐

- **Tumour size**............mm (maximum dimension) Not assessable ☐
  - (T1a =<20 mm; T1b 21–30 mm; T2a 31–50 mm; T2b 51–70 mm; T3 >70 mm).
- **Distance of tumour (or stapled margin if completion lobectomy) from bronchial or medial resection margin:** ............mm

- **Extent of atelectasis/obstructive pneumonia:** None/less than the two categories below ☐

---

REFERRAL AND CLINICAL GUIDELINES FOR LUNG CANCER IN LANCASHIRE & SOUTH CUMBRIA

*Modified May 2014/(June 2014 Chemo/Radiotherapy)*
Involving hilar region but not whole lung (T2) ☐
Involving whole lung (T3) ☐

Microscopic features

Histological type
- Squamous cell carcinoma ☐
- Large cell undifferentiated ☐
- Small cell carcinoma ☐
- Adenocarcinoma ☐
- Adenocarcinoma-in-situ ☐
- Minimally invasive adenocarcinoma (invasive component less than 5 mm) ☐
- Predominant pattern ............... (lepidic, acinar, papillary, micropapillary, solid) ☐
- Mucinous ☐
- Non-mucinous ☐
- Mixed mucinous/non-mucinous (>10% of each) ☐

Combined tumours ☐ (specify ..............................................................)
Other tumour ☐ (specify, e.g. carcinoid, etc. .................................)

Local invasion
- Visceral pleura (T2) ☐
- Parietal pleura/chest wall (T3) ☐
- Mediastinal pleura (T3) ☐
- Pericardium (T3) ☐
- Diaphragm (T3) ☐
- Great vessel (aorta, central pulmonary artery or vein) (T4) ☐
- Atrium, heart (T4) ☐
- Malignant pleural effusion (M1a) ☐

Satellite nodules
- Satellite tumour nodules in same lobe (T3) ☐
- Satellite tumour nodules in different ipsilateral lobe (T4) ☐
- Satellite tumour nodules in contralateral lobe (M1a) ☐

Pleural invasion
- PL0 (no pleural involvement) ☐
- PL1 (breaching of the outer layer of the visceral pleura but no extension to the pleural surface) ☐
- PL2 (breaching of the outer layer of the visceral pleura and extension to the pleural surface) ☐
- PL3 (involvement of the parietal pleura) ☐
Lymph node spread
Ipsilateral hilar/intrapulmonary (node stations 10–14) Submitted □ Involved (N1) □
Ipsilateral mediastinal (node stations 1–9) Submitted □ Involved (N2) □
Contralateral mediastinal, hilar nodes Submitted □ Involved (N3) □
Ipsilateral or contralateral scalene or supraclavicular nodes Submitted □ Involved (N3) □

Margins
Bronchial Clear □ Involved □ N/A □
Mediastinal Clear □ Involved □ N/A □
Vascular Clear □ Involved □ N/A □
Chest Wall Clear □ Involved □ N/A □

Other pathology (non-core)
Emphysema No □ Yes □ Specify degree(mild/moderate/severe)
Interstitial fibrosis No □ Yes □ State cause (if known) ……………………………
Other □ Details: …………………………………

Metastases
Unknown (MX) □ Absent (M0) □ Present (M1a) □ (M1b) □
Details: ………………………

Ancillary data
Epidermal growth factor mutation Yes □ No □ Not assessed □
Other genetic data (specify) ……………………………………………………………

Summary of pathological staging
(Select highest stage from above data; for synchronous primaries, use protocol above;
use prefix ‘y’ for resection during or following treatment and ‘r’ for recurrence after treatment)
…pT ………..pN …………pM ……..
Complete resection at all margins Yes □ No □

SNOMED code:

Comments ………………………………………………………………………………

Signature ………………………………………………………………………………
Date ……../……../……..
PATHWAY FOR SPECIALIST MESOTHELIOMA MDT

LOCAL MDT AGREE TO REFER TO SMDT
- where there are difficulties with diagnosis/staging
- with a PS of 0-2 where radical treatment/trial entry may be option

COMPLETE PROFORMA AND SEND TO BLACKPOOL
Send via email to Heather Lee/Donna Denby@bfwhospitals.nhs.uk

PATHOLOGY
- MJS informed of patient details by HL/DD
- MJS to request slides from relevant Hospital
- need approx 1 week to report

RADIOLOGY
- GMH informed of patient details by HL/DD

SMDT LIST COMPILED BY HL AND SENT TO ALL INVOLVED BY THURSDAY PM
(after checking with Pathology and Radiology)

SMDT MEETING VIDEO CONFERENCE'D 12MD MONDAYS
(Core members present)

SMDT OUTCOMES SENT TO ALL INVOLVED AND RECORD KEPT BY DD

BVH Members
HL – Heather Lee
DD – Donna Denby/Emma Barber
MJS – Dr Sissons/
GMH – Dr Mellor/Dr Howells

Core Members at RPH
Dr Skailes/Dr Appel
Dr Munavvar/ Dr H Singh
Mr Zacharias/Mr Bittar

ALL CORE MEMBERS TO NOMINATE COVER IN THEIR ABSENCE